source
- MoonLake reports all endpoints met in phase 3 trial of sonelokimab for psoriatic arthritisMoonLake Immunotherapeutics said its lead nanobody sonelokimab achieved positive topline results in a phase 3 study of patients with psoriatic arthritis. At week 16, 42.1% of participants reached…
- Latigo and BlossomHill file Nasdaq IPO plans to fund pain and cancer pipelinesLatigo Biotherapeutics and BlossomHill Therapeutics, both based in California, have filed applications to list on the Nasdaq Global Select Market. Latigo aims to raise up to $285.2 million to advan…